Genmab — September 2019

[Plimsoller]

De mener også at der kan være en partnerskabaftale på vej til GEN 3013 i første halvdel af 2020. Det kan enhver jo iøvrigt sige, men det vil da være fint

[Plimsoller]

Fem af produkterne i pipelinen tilskriver de inden værdi endnu, men forsøgsresultater i løbet af 2020 vil måske ændre dette.

[Solsen]

JW har jo også sagt at Gen3013 sikkert får partner i begyndelsen af 2020. Her er lidt til dem der ikke kan få mandagen til at gå: https://openaccess.leidenuniv.nl/bitstream/handle/1887/68231/06.pdf;jsessionid=EA368E16DA44898ADCE7882CC74E096E?sequence=9

[Plimsoller]

Lige mht. timingen for partnerskabsaftaler, så forbeholder jeg mig retten til at være skeptisk

[E_L]

"Then, the important issue is that we treat as many patients [as we can] with daratumumab in the first-line setting. This is the priority." https://www.onclive.com/conference-coverage/imw-2019/daratumumabvtd-regimen-shows-benefit-in-newly-diagnosed-highrisk-multiple-myeloma

[Solsen]

Det var nu blot for at sige, at det ikke er JPMorgans gætteri. Men ok timingen kan være vanskelig

[Plimsoller]

Enig Solsen

[Solsen]

Looks good EL. The huge improvement in MRD negative in Griffin are also a major step toward securing the use of Daratumumab in first line.

[Bulder]

Derfor håber jeg også vi finder et SH-tal for august. Kan måske give et fingerpeg på q3-tallene.

[bibob]

MedWatch. https://medwatch.dk/Medicinal___Biotek/article11618696.ece

[E_L]

@Solsen i hope it will now slowly start to dawn on people that it does not really matter what 2 or 3 drugs are used in first line; just add Dara and make it even better...

[E_L]

BryanGarnier again GENMAB - BUY | DKK1500 vs. DKK1450 (+9%)
Ofatumumab: an additional option for patients more than an Ocrevus’ killer?

At first glance, efficacy seems in line with Ocrevus
Could patients prefer ofatumumab’s at-home dosing?
In other news, Darzalex further expand its grip in MM

[bibob]

Nu kun 100 point op til ATH.

[E_L]

https://twitter.com/Mohty_EBMT/status/1173488771448414208/photo/1

[E_L]

another on MRD @Solsen https://twitter.com/bdermanmd/status/1173219588915585025

[Teller]

[E_L]

https://twitter.com/MM_Hub/status/1173241426198630405 https://twitter.com/MM_Hub/status/1173243010391429120

[Bulder]

I don't quite get the point in the last tweet. Is he suggesting that MoAbs should not be given for induction in some cases?

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

By comparison, ofatumumab can be self-injected by a patient at home every four weeks. Bar-Zohar is keen to point out that just one of the 1882 patients enrolled into the ASCLEPIOS study programme was forced to discontinue ofatumumab therapy due to an injection-related side effect.